Compare RBCAA & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBCAA | SNDX |
|---|---|---|
| Founded | 1974 | 2005 |
| Country | United States | United States |
| Employees | N/A | 298 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 1998 | 2014 |
| Metric | RBCAA | SNDX |
|---|---|---|
| Price | $96.46 | $19.84 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | N/A | ★ $38.69 |
| AVG Volume (30 Days) | 97.7K | ★ 1.3M |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | N/A | ★ 11.56 |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $417,495,000.00 | $172,352,000.00 |
| Revenue This Year | $3.93 | $107.19 |
| Revenue Next Year | N/A | $41.88 |
| P/E Ratio | $125.66 | ★ N/A |
| Revenue Growth | 8.50 | ★ 627.84 |
| 52 Week Low | $63.97 | $13.00 |
| 52 Week High | $102.22 | $25.59 |
| Indicator | RBCAA | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 52.55 | 45.62 |
| Support Level | $88.24 | $19.28 |
| Resistance Level | $102.11 | $22.40 |
| Average True Range (ATR) | 2.26 | 0.98 |
| MACD | -0.68 | 0.00 |
| Stochastic Oscillator | 23.11 | 74.89 |
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking, which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending, and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans, and receipt and payment of federal.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.